


Aztreonam sterile

Site: Tonneis, France

CAS Number: 74863-84-6

Marketed Formulation: Injection




Betamethasone Acetate Sterile

Site: Valladolid, Spain

CAS Number: 987-24-6

Marketed Formulation: Injection - Long acting

Regulatory Submission: expected on 2027




Betamethasone-17,21- Dipropionate Sterile

Site: Valladolid, Spain

CAS Number: 13209-41-1

Marketed Formulation: Injection - Long acting

Regulatory Submission: US DMF



**Disclaimer

This presentation regarding the potential development and manufacture of API and/or drug product ("Product") is for informational purposes only. Curia makes no warranties of any kind, express or implied, including but not limited to any warranty of merchantabilities, fitness for a specific purpose, or non-infringement of any intellectual property rights, with respect to the Product or any information or process contained in or related to this presentation. In no event shall this presentation be deemed an offer for the sale of a Product, or an inducement for Curia's customer to develop the Product or to infringe any third party intellectual property rights. Any decision to enter into a business relationship with Curia regarding the Product or otherwise seek to develop the Product is solely that of Curia's customer. Any business relationship between Curia and the customer with respect to the Product shall be documented in a separate written agreement, containing terms and conditions consistent with industry-standard for similar business relations, including but not limited to indemnification by the customer of Curia for any third party claims related to the development or sale of the Product. This presentation is the confidential information of Curia.

Any "Innovator" referenced in this presentation is a separate company from Curia and its affiliates. Any "Brand" name and trademark referenced in this presentation is owned by the corresponding Innovator or its affiliate, and Curia makes no claim of ownership or license to such names or trademarks.

Products with existing patent protection are intended for development use and Regulatory Purposes only, under 35 U.S.C. 271(e)(1) and article 10.6 of the Directive 2001/EC as amended by the Directive 2004/27/EC.


Budesonide Sterile

Site: Valladolid, Spain

CAS Number: 51333-22-3

Marketed Formulation: Inhalation solution

Regulatory Submission: CEP, China, US DMF




Hydrocortisone Aceponate Sterile

Site: Valladolid, Spain

CAS Number: 74050-20-7

Marketed Formulation: Otic suspension




Hydrocortisone Sodium Phosphate Sterile

Site: Valladolid, Spain

CAS Number: 6000-74-4

Marketed Formulation: Injection

Regulatory Submission: EU DMF



**Disclaimer

This presentation regarding the potential development and manufacture of API and/or drug product ("Product") is for informational purposes only. Curia makes no warranties of any kind, express or implied, including but not limited to any warranty of merchantabilities, fitness for a specific purpose, or non-infringement of any intellectual property rights, with respect to the Product or any information or process contained in or related to this presentation. In no event shall this presentation be deemed an offer for the sale of a Product, or an inducement for Curia's customer to develop the Product or to infringe any third party intellectual property rights. Any decision to enter into a business relationship with Curia regarding the Product or otherwise seek to develop the Product is solely that of Curia's customer. Any business relationship between Curia and the customer with respect to the Product shall be documented in a separate written agreement, containing terms and conditions consistent with industry-standard for similar business relations, including but not limited to indemnification by the customer of Curia for any third party claims related to the development or sale of the Product. This presentation is the confidential information of Curia.

Any "Innovator" referenced in this presentation is a separate company from Curia and its affiliates. Any "Brand" name and trademark referenced in this presentation is owned by the corresponding Innovator or its affiliate, and Curia makes no claim of ownership or license to such names or trademarks.

Products with existing patent protection are intended for development use and Regulatory Purposes only, under 35 U.S.C. 271(e)(1) and article 10.6 of the Directive 2001/EC as amended by the Directive 2004/27/EC.


Hydrocortisone-21- Sodium Succinate Sterile

Site: Valladolid, Spain

CAS Number: 125-04-2

Marketed Formulation: Injection

Regulatory Submission: EU DMF, India




Loteprednol Etabonate Sterile Micronized

Site: Valladolid, Spain

CAS Number: 81934-46-6

Marketed Formulation: Ophthalmic drops (Sunspension)

Regulatory Submission: China, US DMF




Medroxyprogesterone Acetate Sterile

Site: Valladolid, Spain

CAS Number: 71-58-9

Marketed Formulation: Injection

Regulatory Submission: US DMF



**Disclaimer

This presentation regarding the potential development and manufacture of API and/or drug product ("Product") is for informational purposes only. Curia makes no warranties of any kind, express or implied, including but not limited to any warranty of merchantabilities, fitness for a specific purpose, or non-infringement of any intellectual property rights, with respect to the Product or any information or process contained in or related to this presentation. In no event shall this presentation be deemed an offer for the sale of a Product, or an inducement for Curia's customer to develop the Product or to infringe any third party intellectual property rights. Any decision to enter into a business relationship with Curia regarding the Product or otherwise seek to develop the Product is solely that of Curia's customer. Any business relationship between Curia and the customer with respect to the Product shall be documented in a separate written agreement, containing terms and conditions consistent with industry-standard for similar business relations, including but not limited to indemnification by the customer of Curia for any third party claims related to the development or sale of the Product. This presentation is the confidential information of Curia.

Any "Innovator" referenced in this presentation is a separate company from Curia and its affiliates. Any "Brand" name and trademark referenced in this presentation is owned by the corresponding Innovator or its affiliate, and Curia makes no claim of ownership or license to such names or trademarks.

Products with existing patent protection are intended for development use and Regulatory Purposes only, under 35 U.S.C. 271(e)(1) and article 10.6 of the Directive 2001/EC as amended by the Directive 2004/27/EC.


Methylprednisolone-21- Acetate Sterile

Site: Valladolid, Spain

CAS Number: 53-36-1

Marketed Formulation: Injection
- long acting suspension

Regulatory Submission: US DMF




Methylprednisolone-21- Sodium Succinate Sterile

Site: Valladolid, Spain

CAS Number: 172091

Marketed Formulation: Injection

Regulatory Submission: India



**Disclaimer

This presentation regarding the potential development and manufacture of API and/or drug product ("Product") is for informational purposes only. Curia makes no warranties of any kind, express or implied, including but not limited to any warranty of merchantabilities, fitness for a specific purpose, or non-infringement of any intellectual property rights, with respect to the Product or any information or process contained in or related to this presentation. In no event shall this presentation be deemed an offer for the sale of a Product, or an inducement for Curia's customer to develop the Product or to infringe any third party intellectual property rights. Any decision to enter into a business relationship with Curia regarding the Product or otherwise seek to develop the Product is solely that of Curia's customer. Any business relationship between Curia and the customer with respect to the Product shall be documented in a separate written agreement, containing terms and conditions consistent with industry-standard for similar business relations, including but not limited to indemnification by the customer of Curia for any third party claims related to the development or sale of the Product. This presentation is the confidential information of Curia.

Any "Innovator" referenced in this presentation is a separate company from Curia and its affiliates. Any "Brand" name and trademark referenced in this presentation is owned by the corresponding Innovator or its affiliate, and Curia makes no claim of ownership or license to such names or trademarks.

Products with existing patent protection are intended for development use and Regulatory Purposes only, under 35 U.S.C. 271(e)(1) and article 10.6 of the Directive 2001/EC as amended by the Directive 2004/27/EC.

● Catalogue APIs ● R&D APIs